Roche says Gazyvaro approved in Europe against leukemia

Whatsapp News

rocheZURICH – Roche said Tuesday European regulators approved its drug Gazyvaro, or obinutuzumab, for patients with chronic lymphocytic , boosting Swiss group’ line-up of new treatments.

new medicine is an follow- medicine Swiss drugmaker’ $7 billion-a-year Rituxan, or MabThera, and Roche is hoping switch as many patients as possible newer product before Rituxan faces cheaper copies.[eap_ad_2]

move endorses a favorable recommendation in European Medicine Agency’ Committee for Medicinal for Human Use (CHMP), which are normally followed by the European Commission. (Reuters)[eap_ad_3]